Haha. Not likely. Have you noticed that slump in price over the last ten days is on much lower volume than the average from the last few months. Like Map said: "weak hands," who will all be regretting it after one of the looming 'news balloons' pops.
That probably explains the strange (weak) price action this week, and especially today when a small positive news story should have given a little bump. So much going on at the moment, aside from HAE which is what drove it to $13 originally. P will be approved anyday and eventually we will have the best EBOLA drug available (and the Govt. knows that and keeps shelling out more cash to speed the process along). We'll be back heading towards $20 again soon enough.
It's Beer-thirty here now, so I gotta go.
"Next week we should hear about more funding.." and maybe next week (or at least sometime soon) we will hear about FDA approval of Peramivir. That's a big news event that is due anytime.
OK then, not SRPT. Almost certainly TKMR with T-705 a distant second and 4430 a bit further behind that. I will eat my hat at your Vegas golf gathering next year if it turned out that it was 4430 (and sadly, I have all my hats custom-made from barbed wire and glass shards).
I wish that 4430 was given a try but I doubt it very much. The lack of any human safety info probably kills any chance. If it was my brother I would ask for 4430, but...
More (much) likely candidates:
AVI 7537 (Sarepta)
Here is the bit from the WHO meeting document that is being construed as 4430 will not be used for EBOLA.
Studies of this anti-viral in animals
indicate 83% to 100% survival in
rodents with EVD. It is also
effective in animals 48 hours after
infection with the lethal Marburg
virus, which belongs to the same
family as Ebola. Testing for EVD
in monkeys is underway.
No human safety studies or data
available. Safety studies are
Needs animal treatment and
protection data for EVD before it
can be considered. No material
is currently available for field use.
Haha. From your lips to God's ears, eh Copper? That would be sweet... but $130+ per share? I don't think so. If Big Pharma offered $30 per share then shareholders would force the sale.
The RAPIACTA® royalty stream from Shionogi & Co. (“Shionogi”), the partner of BioCryst Pharmaceuticals, Inc. (the “Company”) in Japan, was insufficient to pay the accrued interest in arrears on the non-recourse PhaRMA Notes by the September 1, 2014 payment date and an event of default has occurred with respect to the PhaRMA Notes. As a result of the event of default, the holders of the PhaRMA Notes may pursue acceleration of the PhaRMA Notes, may foreclose on the collateral securing the PhaRMA Notes and the equity interest of the Company in its wholly-owned subsidiary, JPR Royalty Sub LLC (“Royalty Sub”) and exercise other remedies available to them under the indenture in respect of the PhaRMA Notes. In such event, the Company may not realize the benefit of future royalty payments that might otherwise accrue to the Company following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the Company believes the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company may incur costs associated with liquidating the related currency hedge agreement, which would no longer be required in the event of foreclosure or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub, the Company does not currently expect an event of default on the PhaRMA Notes to have a significant impact on the Company’s future results of operations or cash flows.
AstraZeneca has dozens of drugs approved and on sale, and dozens more in Trials. You can't even compare to our "couple" of molecules. Then there is the tax inversion thing which adds Billions more in value.
From the Financial Times:
"Analysts say AstraZeneca remains an attractive target for Pfizer, which is looking for acquisitions to replenish its pipeline and to absorb some of the tens of billions of dollars of cash it has trapped offshore.
By acquiring AstraZeneca and shifting its official home to the UK, Pfizer would shelter its overseas revenues from the 35 per cent US corporate tax rate."
"Except you are a idiot." Come on! It's "an idiot"
You can't call someone out for being stupid, while being stupid with your own grammar.
Nice to see BCRX take another actual step with 4430.